Who owns SNYWhat SNY owns
What Sanofi owns
The company's own 13F portfolio · as of 2026-03-31 · long US-listed stakes only — private holdings, bonds and cash are not disclosable on a 13F
$336.0M
disclosed stock portfolio
9
positions
31.4%
in MeiraGTx
Positions, as of 2026-03-31
ordered by filed value · % of book = share of the disclosed stock portfolio · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | MeiraGTx Holdings plc | 12.2M | $105.6M | 31.4% |
| 2 | INBXInhibrx Biosciences, Inc. | 1.2M | $77.8M | 23.2% |
| 3 | NVAXNovavax | 6.9M | $56.0M | 16.7% |
| 4 | ANABAnaptysBio | 821,917 | $30.4M | 9% |
| 5 | Agomab Therapeutics NV | 2.8M | $29.2M | 8.7% |
| 6 | MapLight Therapeutics Inc. | 912,041 | $18.5M | 5.5% |
| 7 | Immuneering Corp | 2.7M | $14.3M | 4.2% |
| 8 | Eledon | 814,980 | $2.5M | 0.7% |
| 9 | Q32 Bio Inc. | 244,083 | $1.6M | 0.5% |
Source: SEC Form 13F-HR filed by Sanofi (CIK 1121404), reporting period 2026-03-31. Values are quarter-end filed marks. Research, not investment advice.